Retatrutide Explained: Is It the Next Mounjaro?

What is retatrutide?

Retatrutide is an investigational medicine being developed by Eli Lilly as a potential treatment for obesity and related metabolic conditions.

It has attracted significant attention because it is designed to activate three hormone receptors:

• GLP-1
• GIP
• Glucagon

This makes retatrutide different from both Wegovy (semaglutide) and Mounjaro (tirzepatide).

Wegovy activates the GLP-1 receptor, while Mounjaro activates GLP-1 and GIP receptors. Retatrutide adds glucagon receptor activity, creating what is commonly described as a triple agonist.

The theory behind this approach is that combining these three pathways could produce a stronger effect on appetite, energy balance, glucose metabolism and body weight.

Early clinical trials have generated considerable interest. However, an important distinction remains:

Retatrutide is not currently authorised for routine use in the UK.

The UK government has specifically warned against online claims surrounding retatrutide and confirmed that it has not been authorised for use in the UK.

Why is everyone talking about retatrutide?

The excitement surrounding retatrutide comes largely from its clinical trial results.

In the Phase 2 trial published in the New England Journal of Medicine, retatrutide produced substantial, dose-dependent weight loss over 48 weeks in adults with obesity.

More recently, Phase 3 results have produced even more attention.

In the TRIUMPH-1 Phase 3 trial, participants receiving the highest studied dose of retatrutide lost an average of 28.3% of their body weight at 80 weeks. Around 45.3% of participants achieved at least 30% weight loss.

These results are impressive and help explain why retatrutide is sometimes described online as the “next Mounjaro” or the next generation of weight-loss medication.

But there is an important caveat.

The results from different clinical trials should not automatically be compared as though the medicines were tested against each other in identical conditions.

And while retatrutide has produced very promising results, it remains an investigational medicine.

How does retatrutide work?

To understand why retatrutide is different, it helps to understand the three hormonal pathways it targets.

GLP-1

GLP-1, or glucagon-like peptide-1, is a hormone involved in appetite regulation and blood glucose control.

GLP-1 receptor activation can:

• reduce appetite
• increase feelings of fullness
• slow gastric emptying
• reduce food intake
• improve blood glucose regulation

This is the pathway targeted by medicines such as semaglutide.

GIP

GIP stands for glucose-dependent insulinotropic polypeptide.

GIP is another hormone involved in nutrient sensing and metabolic regulation.

Tirzepatide activates both GIP and GLP-1 receptors, which is one reason it is described as a dual agonist.

Glucagon

Glucagon has an important role in energy metabolism.

Unlike GLP-1, which generally reduces appetite and supports glucose regulation, glucagon signalling can influence energy expenditure and the way the body handles stored energy.

Retatrutide combines activity at all three receptors.

The aim is therefore not simply to suppress appetite, but to influence several biological systems involved in body weight and metabolism simultaneously.

Retatrutide vs Mounjaro: what is the difference?

Mounjaro contains tirzepatide, which activates the GIP and GLP-1 receptors.

Retatrutide activates:

GIP + GLP-1 + glucagon

That additional glucagon activity is the major pharmacological difference.

Mounjaro is already an established prescription treatment for weight management in appropriate patients, whereas retatrutide is still undergoing clinical development.

There is also now a clinical trial specifically investigating retatrutide compared with tirzepatide in adults with obesity.

This distinction matters because some headlines describe retatrutide as “better than Mounjaro”, but the answer is more complicated.

Until appropriate head-to-head evidence is available and regulators have reviewed the complete evidence package, it would be premature to say that retatrutide is definitively better than Mounjaro.

Is retatrutide more effective than Mounjaro?

This is one of the biggest questions surrounding the drug.

The available retatrutide results are certainly impressive.

However, cross-trial comparisons are not the same as a head-to-head clinical trial.

Mounjaro has already demonstrated substantial weight loss in large clinical trials. In the SURMOUNT-1 trial, adults with obesity treated with tirzepatide experienced substantial and sustained reductions in body weight over 72 weeks.

Retatrutide's Phase 3 TRIUMPH-1 results reported an average 28.3% reduction at 80 weeks at the highest dose studied.

Those numbers are highly encouraging, but they should not be interpreted as proof that an individual taking retatrutide would necessarily lose more weight than an individual taking Mounjaro.

Differences in study design, patient populations, treatment duration, dose escalation and other factors can affect results.

The most reliable answer will come from properly designed head-to-head trials.

What are the retatrutide clinical trial results?

Retatrutide's development has progressed from early-stage studies into a large Phase 3 programme.

Phase 2 results

The Phase 2 trial published in the New England Journal of Medicine found dose-dependent reductions in body weight over 48 weeks. The study provided the initial evidence that simultaneously targeting GLP-1, GIP and glucagon could produce substantial weight loss.

The results were significant enough to support progression into larger Phase 3 trials.

TRIUMPH-1

The first major Phase 3 obesity results generated considerable attention in 2026.

At 80 weeks, participants receiving the highest dose achieved an average body-weight reduction of 28.3%, according to Lilly's reported topline results. 45.3% achieved at least 30% weight loss.

TRIUMPH-2

Additional Phase 3 results have also been announced in people with obesity or overweight and type 2 diabetes.

At the highest dose, participants lost up to an average of 20.8% of body weight at 80 weeks.

This is particularly relevant because people with type 2 diabetes can respond differently to weight-management treatment.

The wider TRIUMPH programme is continuing to investigate retatrutide across different populations and health conditions.

What are the side effects of retatrutide?

Because retatrutide is still investigational, its complete long-term safety profile has not yet been established.

Clinical trials have reported gastrointestinal side effects, including symptoms such as:

• nausea
• diarrhoea
• vomiting
• constipation
• reduced appetite
• abdominal symptoms

These types of gastrointestinal effects are also commonly associated with existing incretin-based weight-management medicines.

However, it is important not to assume that the safety profile of retatrutide will be identical to Mounjaro or Wegovy.

Retatrutide has a different mechanism of action because it also activates the glucagon receptor.

Researchers therefore continue to monitor its safety carefully as the Phase 3 programme progresses.

Long-term safety data and regulatory review will be essential before routine prescribing can be considered.

Is retatrutide approved in the UK?

No.

As of September 2026, retatrutide is not authorised for routine use in the UK.

The MHRA has specifically warned about illegal and unlicensed weight-loss medicines containing retatrutide. The UK government has also recently warned the public not to be tempted by online hype surrounding the drug.

This means retatrutide should not be treated like an approved prescription medicine such as Mounjaro or Wegovy.

There is currently no routine UK pharmacy supply of licensed retatrutide for weight management.

Can you buy retatrutide in the UK?

You may see websites, social media accounts and online sellers claiming to offer retatrutide.

That does not mean that the product is legitimate.

The MHRA has taken enforcement action against illegal manufacturing and distribution of unlicensed weight-loss medicines, including products described as retatrutide.

The UK government has warned that products being sold illegally have not been properly assessed for their safety, quality or effectiveness and may not even contain what the seller claims.

For this reason, purchasing “retatrutide” from an unregulated website, social media seller or research-peptide supplier is not a safe alternative to licensed medical treatment.

Do not use an unlicensed retatrutide product simply because it is marketed as the same medicine being investigated in clinical trials.

When will retatrutide be available in the UK?

There is currently no confirmed UK launch date for retatrutide.

Before it can become routinely available, the medicine must go through the appropriate regulatory process.

This includes the submission and review of evidence concerning:

• efficacy
• safety
• manufacturing quality
• dosing
• adverse effects
• benefits and risks
• appropriate patient populations

The MHRA would then need to determine whether the medicine should receive UK marketing authorisation.

If authorised, access would still depend on how the medicine is subsequently made available within the UK healthcare system.

It is therefore too early to give patients a definitive date for when retatrutide will become available.

Is retatrutide the next Mounjaro?

It could become an important next-generation treatment, but calling it “the next Mounjaro” is currently more of a description of its potential than an established clinical fact.

There are several reasons for the excitement.

Retatrutide:

• targets three metabolic hormone receptors
• has produced substantial weight loss in clinical trials
• is being investigated in large Phase 3 studies
• could potentially become an important future treatment for obesity
• may offer another option for people who need significant weight reduction

But there are also unanswered questions.

We still need to understand its long-term safety, how it compares directly with existing treatments, which patients benefit most, how sustainable the weight loss is, and how regulators will assess its overall benefit-risk profile.

So the most accurate description is:

Retatrutide is a highly promising investigational weight-loss medicine, not yet an approved replacement for Mounjaro.

Retatrutide vs Wegovy vs Mounjaro

There are currently three very different stages of development to understand.

Wegovy contains semaglutide and activates the GLP-1 receptor.

Mounjaro contains tirzepatide and activates the GLP-1 and GIP receptors.

Retatrutide activates GLP-1, GIP and glucagon receptors but remains investigational.

If you are considering weight-loss medication today, the practical question is therefore not necessarily which future medicine sounds most powerful.

It is:

Which approved treatment is clinically appropriate for me now?

SynovaMed provides information and clinical assessment for approved weight-management treatments, including Mounjaro and Wegovy.

You can also read our guide to weight loss injections and what you need to know.

Should I wait for retatrutide before starting Mounjaro?

For most people, waiting for an investigational medicine that may become available in the future is not necessarily the best approach.

Mounjaro is already an authorised treatment for appropriate patients, with substantial clinical evidence supporting its use for weight management.

Retatrutide's future potential does not change the fact that it is currently unavailable as a routinely authorised UK treatment.

If you are eligible for weight-management treatment now, a clinician can discuss the approved options available to you.

Treatment decisions should be based on your current health, medical history, weight-management goals, potential benefits, side effects and individual preferences.

What if Mounjaro is not working for me?

If you are already taking Mounjaro and are wondering whether retatrutide might be better, do not stop or change your treatment without discussing it with your prescriber.

There are several reasons why someone may experience slower-than-expected weight loss on Mounjaro.

These can include:

• being early in treatment
• still progressing through dose escalation
• inconsistent dosing
• changes in calorie intake
• reduced physical activity
• a temporary weight-loss plateau
• other medicines
• underlying health factors
• individual differences in response

Before considering a different medicine, it is usually sensible to assess your current treatment properly.

Read our guide to why you may not be losing weight on Mounjaro or Wegovy.

What does the future of weight-loss medication look like?

Retatrutide is part of a broader shift in obesity medicine.

Researchers are increasingly investigating medicines that target multiple biological pathways involved in appetite, glucose regulation and energy metabolism.

The progression from GLP-1 receptor agonists to dual agonists such as tirzepatide and now triple agonists such as retatrutide demonstrates how quickly this field is developing.

Future treatments may potentially offer:

• greater average weight loss
• improved metabolic outcomes
• different dosing options
• better treatment personalisation
• new options for people who do not respond adequately to existing medicines

But greater weight loss does not automatically mean a treatment is better for every patient.

A medicine must also demonstrate an acceptable safety profile, tolerability, manufacturing quality and long-term clinical benefit.

That is why regulatory approval and high-quality clinical evidence remain essential.

Frequently Asked Questions About Retatrutide

What is retatrutide?

Retatrutide is an investigational once-weekly medicine being developed by Eli Lilly for obesity and related metabolic conditions. It activates GLP-1, GIP and glucagon receptors, making it a triple agonist.

Is retatrutide the same as Mounjaro?

No. Mounjaro contains tirzepatide and activates GLP-1 and GIP receptors. Retatrutide activates GLP-1, GIP and glucagon receptors.

Is retatrutide better than Mounjaro?

It is too early to say. Retatrutide has produced impressive weight-loss results in clinical trials, but direct comparisons with Mounjaro are needed before concluding that one is superior.

Is retatrutide approved in the UK?

No. As of September 2026, retatrutide has not been authorised for routine use in the UK. The UK government has warned people against buying unlicensed retatrutide products online.

Can I buy retatrutide privately in the UK?

You should not purchase retatrutide from unregulated websites or sellers. Products marketed outside authorised clinical research may not have been assessed for quality, safety or effectiveness.

How much weight can you lose with retatrutide?

In the TRIUMPH-1 Phase 3 trial, the highest dose produced an average 28.3% reduction in body weight at 80 weeks. However, trial results are averages and do not predict exactly how much weight an individual person would lose.

Is retatrutide a GLP-1?

Retatrutide is not simply a GLP-1 medicine. It activates three receptors: GLP-1, GIP and glucagon.

Is retatrutide a peptide?

Retatrutide is an investigational peptide-based medicine. However, products sold online as “research peptides” should not be confused with an authorised pharmaceutical product.

When will retatrutide be available in the UK?

There is currently no confirmed UK availability date. Retatrutide would need to complete the necessary regulatory process before routine prescribing could take place.

Should I wait for retatrutide instead of taking Mounjaro?

Not necessarily. Mounjaro is an authorised treatment that can be prescribed to eligible patients now, whereas retatrutide remains investigational. A clinician can help you assess the treatments currently available to you.

The Bottom Line

Retatrutide is one of the most closely watched developments in modern obesity medicine.

Its triple-action mechanism, targeting GLP-1, GIP and glucagon, has produced impressive weight-loss results in clinical trials. The latest Phase 3 data have strengthened interest in its potential as a future treatment for obesity.

But there is an important distinction between promising clinical trial results and an approved medicine.

As of September 2026, retatrutide is not authorised for routine use in the UK. The MHRA and UK government have also warned about unlicensed retatrutide products being sold online.

So, is retatrutide the next Mounjaro?

It could become one of the most important next-generation weight-management medicines, but it is too early to call it a replacement for Mounjaro.

For patients looking for treatment today, the focus should remain on approved medicines, appropriate clinical assessment and long-term weight-management support.

Explore SynovaMed's weight loss injection service to learn more about currently available treatment options.